Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edaravone Dexborneol for acute ischemic stroke due to branch atheromatous disease
ChiCTR2600132225Phase 4Not yet recruiting
- Sponsor
- Foshan First People's Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of edaravone dexborneol in ischemic stroke and branch atheromatous disease (BAD) (2 arms), sponsored by Foshan First People's Hospital. Primary endpoint: Percentage change in infarct volume. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
edaravone dexborneol
03
Conditions
ischemic strokebranch atheromatous disease (BAD)
Beyond the preview
Go deeper on ChiCTR2600132225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132225.